An FDA panel is slated to review the NDA for Baricitinib, proposed for the treatment of patients with moderate-to-severe rheumatoid arthritis, on April 23, 2018.Baricitinib, a once-daily oral JAK inhibitor, is co-developed by Eli Lilly and Co. (LLY) and Incyte Corp. (INCY).In April 2017, the FDA had turned down Baricitinib, seeking additional clinical data on the drug’s dosing and safety profile. Therefore, Lilly and Incyte were not hopeful of resubmitting the NDA until 2019. But Lilly made a surprise move by refiling it much earlier than expected, i.e., in December 2017.The FDA’s final decision on Baricitinib is expected to be announced in June 2018.Baricitinib was approved by the European Commission, last February, under brand name Olumiant, for the treatment of moderate-to-severe active rheumatoid arthritis. Following the European Commission approval, Incyte received a milestone payment of $65 million from Lilly.INCY closed Tuesday’s (Mar.27) trading at $85.03, down 1.55%.